GlassScriptPhysician profile
Lori Dawn Rule
NPI 1073596433
$11,057.63
in general payments reported to CMS, 2019-2025
28 companies · $3,061 in 2025
The $3,061 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $779 · 2022: $2,023 · 2023: $2,445 · 2024: $2,751 · 2025: $3,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,804 · Education: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,803.91 |
| Education | $452.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,035.84 | 2021-2025 | |
| Janssen Biotech, INC. | $1,242.69 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $897.80 | 2021-2025 | |
| Lilly USA, LLC | $877.39 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $755.04 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $684.39 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $624.40 | 2021-2025 | |
| Genzyme Corporation | $610.49 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $605.03 | 2021-2025 | Winlevi, Odomzo, Blu-U |
| Incyte Corporation | $521.82 | 2021-2025 | Opzelura |
| Ucb, INC. | $390.48 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $370.07 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $296.08 | 2022-2025 | Nemluvio |
| Leo Pharma INC. | $290.50 | 2022-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $194.38 | 2024-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $112.29 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $108.47 | 2024 | Siliq |
| Dermavant Sciences, INC. | $96.91 | 2022-2024 | Vtama |
| Almirall LLC | $83.17 | 2022-2023 | Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.73 | 2024 | Spevigo |
| Kyowa Kirin, INC. | $41.70 | 2022-2025 | |
| Organogenesis INC. | $39.40 | 2024 | |
| Genentech USA, INC. | $29.83 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $29.55 | 2023-2024 | Idacio |
| Organon LLC | $24.55 | 2025 | Vtama, Nexplanon |
| Botanix Sb INC | $17.29 | 2025 | Sofdra |
| Sandoz INC. | $16.90 | 2024 | Hyrimoz |
| Conmed Corporation | $15.44 | 2025 | Visiclear |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Rule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.